A life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto.
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.
The firm has no specific requirement for the company & management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Author: Next Phase Admin
Hot Investor Mandate: Major Financial Institution with Billions in AUM Actively Seeks Therapeutics and Medical Device Investment Opportunities, Mostly in Europe
A major financial institution based in Western Europe managing venture capital funds totaling to several billion, is significantly focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-8 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in companies in Europe.
The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health. The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics (mainly First-In-Class), including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases. The firm invests from preclinical-stage companies through to Phase II.
The firm prefers to invest in companies based in the country where their headquarters are located, but will consider opportunities elsewhere in Europe: for companies in this country, the firm is typically a lead or co-lead investor, but in other regions the firm prefers to be a follow-on investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based Pharmaceutical Seeks In-Licensing and Collaboration Opportunities With Promising Technologies in Pain and Inflammatory Diseases
A pharmaceutical company dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care, is vastly investing to expand their presence from its domestic roots to become a Global Specialty Pharma. To achieve above goal, the firm is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.
The firm Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the firm is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the firm is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Therapeutics Accelerator Actively In-Licenses Assets from Pre-Clinical to Early Clinical Stages of Development, Considering Opportunities Across All Modalities
A therapeutic accelerator looks to in-license therapeutics assets from inventors/founders, and fund the assets’ development through clinical proof-of-concept. The firm is looking for assets throughout the United States and is actively seeking new opportunities. The firm has signed a partnership with a major VC firm, who will advise on current and future investments.
The firm is currently looking for therapeutic assets in pre-clinical through early clinical stages of development. The firm is open in terms of indication and will consider both small molecules and biologics, and will also consider drug repurposing opportunities. The firm looks to in-license these assets and accelerate their development through to clinical proof-of-concept, at which point the firm looks to partner the asset with pharmaceutical firms or other investors who will complete the commercialization of the asset. The firm has signed strategic partnerships with major pharma, regarding products in cardiovascular, metabolic, neuroscience, and immunology indications.
The firm focuses on the strength of the technology when evaluating in-licensing opportunities. The company leverages a capable and connected team and advisors for the development, funding, active management, and partnering of its portfolio of therapeutic products.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
400 Reasons to Not Miss Out
By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN
Are you looking for early-stage investors? Digital RESI, June 7-9 is the (virtual) place to be! Don’t take my word for it, though. Check out the investors and strategic partners who are already registered for Digital RESI June and decide for yourself how you want to connect with 400+ top early-stage investors and strategics. You can book meaningful meetings with the right players on the powerful RESI Partnering Platform, and you still have a chance to compete in the Innovator’s Pitch Challenge. Be sure to register by this Friday, May 6 to save $200 on registration.
Confirmed Investors and Strategic Partners*
*As of May 4, 2022
Building the Perfect Pitch
By Karen Deyo, Director of Investor Research, Israel BD, LSN
A perfectly honed pitch is an important part of a startup’s bag of tricks. Many think that having a good pitch is easy because no one knows their company better than they do, and telling people about it is simple enough, right? Wrong! Building a concise pitch with the right amount of information to tell enough of the story to catch an investor’s attention can be a long and arduous process. When working with some of our branding and messaging clients, the elevator pitch can go through dozens of drafts before finding the right balance.
A good pitch should give investors a snapshot of your technology, your stage of development, what makes your technology unique, what you are looking to raise and what milestones you are looking to achieve. Some companies may also choose to highlight any relevant experience with the management team, the involvement of a KOL, or maybe a key partnership that they have developed. Each elevator pitch is unique, depending on the company and what part of their story is crucial to highlight. The one thing that all pitches have in common is that they take a lot of practice to perfect. However, you cannot practice in a vacuum – getting solid feedback is a critical part of developing a solid pitch.
This is where pitch sessions, like RESI’s Innovator’s Pitch Challenge (IPC) come in. The IPC provides a chance to hone your pitch, practice pitches in different lengths, from the 4-minute prerecorded pitch to the 1-minute live pitch during the Q&A session and get a glimpse of what questions an investor may ask for clarification. Participating in pitch sessions like the IPC gives you a glimpse into what questions investors are frequently asking you. This may indicate an area of your pitch that needs more work, or a part of your company strategy that you should develop more fully to appeal to more investors. Joining the IPC is a wonderful tool to help you make a great first impression.
Join Life Science Nation for a FREE Bootcamp in preparation for the Innovator’s Pitch Challenge.
|
Tuesday, May 10, 11AM EDT
|
|
|
Preparing to Pitch at RESIÂ
|
|
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.
|
|
The application deadline for the IPC has been extended, so it’s not too late to apply for the IPC for Digital RESI June – apply here!
The Voices of RESI
By Rory McCann, Marketing Manager & Conference Producer, LSN
Panels are an integral part of the Redefining Early Stage Investments (RESI) conference series. They cover topics relevant to the fundraising entrepreneur, but they also feature prominent voices from both sides of the deal-making equation. RESI panels demystify the investment process by highlighting speakers from various investment firms representing different types of capital, including corporate venture, impact investors, endowments, foundations, private equity, family, offices, angels, incubators, and accelerators. RESI panels also shine a spotlight on entrepreneurs who have successfully raised funds and are willing to share their early-stage journeys, as well as best lessons learned along the way.
Check out the most recent list of speakers joining Digital RESI June who are participating virtually to shed light on the ever-changing landscape of early-stage life science and healthcare. Join them June 7-9 and save $200 on early bird rates by Friday, May 6.
 Michael Baran Executive Director, WRD and Principal Pfizer Ventures |
 Kaitlin Christine Founder & CEO Gabbi |
 Marina Cortes Venture Partner SandBanks Capital |
 David Gordon Head of Investments Longliv Ventures |
 James Hardiman Partner Data Collective |
 Sarah Hippert Program Manager Techstars |
 Brenda Hogan Chief Investment Officer Ontario Capital Growth Corporation |
 Baudouin Hue Partner Karista |
 Ozan Isinak President, Central Canada Keiretsu Forum |
 Kristin King Member Boston Harbor Angels |
 Bill Kuziel Analyst and Investor MedPro Investors |
 Sebastien Latapie Principal Dynamk Capital |
 Seo Lee Principal SV Investment |
 Eric Levitan Founder and CEO Vivo |
 Ben Nahir Venture Principal Elevate Capital |
 Maria Luisa Pineda Founder & CEO Envisagenics |
 Gayathri Radhakrishnan Senior Director Venture Capital – AI Fund Micron Ventures |
 Katherine Relle Vice President Accelmed |
 Jane Rho Investor DaVita Venture Group |
 Surbhi Sarna Group Partner Y Combinator |
 Yaniv Sneor Founding Member Mid Atlantic Bio Angels |
 Eran Steinberg Imaging Arts |
 Vangelis Vergetis Co-Founder & Executive Director Intelligencia.ai |
 Sa’ar Yaniv Director of Business Development Fortress Biotech |
 Derek Yuan Senior Associate LYFE Capital |
 Lu Zhang Managing Partner Fusion Fund |
 Alex Zhavoronkov CEO InSilico Medicine |
| Â |  Cheryl Zimberlin Investment Director M Ventures |
 |
